Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial
Authors' conclusion
Acute administration of exenatide to comatose patients in the intensive care unit after OHCA is feasible and safe. Exenatide did not reduce neuron-specific enolase levels and did not significantly improve a composite end point of death and poor neurological function after 180 days.
Study context
- Population
- Comatose patients resuscitated from out-of-hospital cardiac arrest (OHCA), with standardized intensive care incl. targeted temperature management
- Participants
- 120 patients
- Comparison
- Exenatide vs placebo
- Primary endpoint
- Coprimary: feasibility (study drug initiated in >90% patients within 240 minutes of return of spontaneous circulation) and efficacy (geometric area under the neuron-specific enolase curve)
- Follow-up
- 24 to 72 hours after admission
Methodological detailsdouble-blind, 2-centre
- Double-blind
- 2-centre
Primary result
As reported in the abstract
Feasibility and area under the neuron-specific enolase curve
Study drug initiated within 240 minutes of return of spontaneous circulation
96%
Secondary outcomes
Median blood glucose · 8 hours after admission
P < 0.0001
Composite of death and poor neurological function (Cerebral Performance Category 3 to 5) · 30 and 180 days
- No significant difference between groups
Safety
- Adverse events rare, no significant difference between groups
Original publication
Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial. Circulation. Published 12 November 2016. doi:10.
Summarised from the published abstract; every number is checked against it